AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs.

Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 mutation and XIAP deficiency (primary HLH), Macrophage Activation Syndrome (secondary HLH), Adult onset Still's Disease and others.

AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases.

Extensive Phase I, Ib and II clinical trials demonstrated a high tolerance and an excellent safety profile of our drug. We have advanced clinical programs in primary HLH: NLRC4  mutation and XIAP deficiency and in Adult onset Still’s Disease.


March 7, 2023 - AB2 Bio completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH

August 25, 2021 - AB2 Bio expands Phase 3 trial of Tadekinig alfa in monogenic HLH